Abstract.
The present study examines the effect of rofecoxib in combination with topiramate (a newer antiepileptic) against PTZ (80 mg/kg, i. p.)-induced chemoconvulsions in mice. Pretreatment with rofecoxib (1.0 and 5.0 mg/kg., i. p.) or topiramate (50 and 100 mg/kg., i. p.) dose dependently protected the animals against PTZ-induced convulsions. However, the lower dose of neither rofecoxib (0.5 mg/kg., i. p.) nor topiramate (25 mg/kg., i. p.) modified the latency of any of the phase of PTZ-induced convulsions. When a subeffective doses of rofecoxib (0.5 mg/kg, i. p.) was coadministered with a subprotective dose of topiramate (25 mg/kg, i. p.), there was no increase in onset latency of myoclonic jerks but an increase in the latency for clonus and extensor phase were observed. Rofecoxib may be used as an adjunct therapy with topiramate in the treatment of epilepsy.
Similar content being viewed by others
Author information
Authors and Affiliations
Corresponding author
Additional information
Received 26 September 2007; revised 16 October/7 November 2007; accepted 26 November 2007
Rights and permissions
About this article
Cite this article
Dhir, A., Akula, K.K. & Kulkarni, S.K. Rofecoxib potentiates the anticonvulsant effect of topiramate. Inflammopharmacol 16, 83–86 (2008). https://doi.org/10.1007/s10787-007-7007-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10787-007-7007-6